SIMCERE PHARMA (02096) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 3.585 billion, representing a year-on-year increase of 15.14%. Net profit reached RMB 604 million, up 32.2% compared to the same period last year. Basic earnings per share were RMB 0.25. The adjusted profit attributable to equity shareholders of the company was RMB 651 million, compared to RMB 538 million in the same period last year, representing an increase of 21.1%.

According to the announcement, as of the date of this announcement, the group has successfully expanded its commercialized innovative drug portfolio to ten products: Endostar®, Aidexin®, Xinbixin®, Envida®, Cosela®, Xinuoxin®, Enlito®, Xinbixin® sublingual tablets, Keweike®, and Enzeshu®. These products cover neuroscience, oncology, autoimmune, and anti-infection therapeutic areas, offering significant market potential and synergistic benefits. For the six months ended June 30, 2025, innovative drug business revenue was RMB 2.776 billion, accounting for 77.4% of total revenue.